Interview: To help the global epidemic prevention and control with safe and effective Chinese vaccines - Visiting China Pharmaceutical Group China Biological Chairman Yang Xiaoming

Many countries around the world are continuing to promote the new crown vaccination, China's vaccine safety, effectiveness, accessability has been recognized by many countries.
Yang Xiaoming, chairman of China National Pharmaceutical Group China Biotechnology Co., Ltd. and chief scientist of the national "863" vaccine program, said in an exclusive interview with Xinhua News Agency recently that building a global immunization defense line through vaccination requires concerted efforts by all countries, and that Chinese companies are fulfilling their obligations to promote equitable distribution of vaccines.
Yang Xiaoming said that the global population of more than 7 billion people, the new coronavirus susceptible population is the whole population, the need for countries around the world in vaccination, personal protection, community management and other aspects of joint efforts to effectively control the outbreak.
said China's decision to provide 10 million doses of the vaccine to the New Coronary Pneumonia Vaccine Implementation Program, mainly for developing countries, is urgently needed to deliver on its commitment to make the new crown vaccine a global public product through practical action. According to data provided by
Pharmaceutical Group, the current Chinese bio-new crown inactivated vaccine has been approved for emergency use in more than 10 countries and regions, including Hungary, Seychelles, Pakistan and Morocco, and is listed in the United Arab Emirates and Bahrain, and is approved for conditional listing in China.
Yang Xiaoming said that at present, China Pharmaceutical Group, such as the production of domestic vaccine exports to developing countries, these countries basically do not have the ability to develop or produce new crown vaccines, more than other countries need vaccines, Chinese enterprises are to promote the fair distribution of vaccines due obligations.
developing and less developed countries have very limited procurement capacity and conditions for vaccine storage and transportation compared to developed countries.
yang Xiaoming believes that China's new crown vaccine costs lower, production is large enough, storage and transportation conditions are also 2 to 8 degrees Celsius, with many countries existing vaccine storage and transportation conditions consistent, no need to reconstruct cold chain system facilities, higher access, can better help third world countries outbreak prevention and control.
In Yang Xiaoming's view, China's many new crown vaccines, including inactivated vaccines, have been in the "first square" of global research and development of new crown vaccines, indicating that over the past 40 years of reform and opening up, China's vaccine industry as a whole research and development capacity, process equipment and regulatory level significantly improved, from "follow", "run", and even individual varieties "lead" breakthrough.
Now our research and development production process is completely different from the inactivated vaccine process a few decades ago, can be said to be a change - there is an improvement in the process, a technological breakthrough.
" Yang Xiaoming said, China National Pharmaceutical Group's new bio-crown inactivated vaccine using advanced cell culture technology, purification technology, such as high production efficiency, quality control indicators have reached the international advanced level.
chinese vaccine companies are working overtime to expand production capacity to ensure that the new crown vaccine is sent to urgently needed places as soon as possible.
Yang Xiaoming said that this year, China National Pharmaceutical Group's bio-new crown vaccine production capacity of more than 1 billion doses, "to help the global distribution of vaccines fairly, from a corporate point of view, is under the premise of safety norms more and faster production of high-quality vaccines."
Penci Party Source: Xinhua News Agency Copyright Notice: All text, images and audio and video materials on this website that indicate "Source: Mets Medicine" or "Source: MedSci Original" belong to Mace Medical, and without authorization, no media, website or individual may reproduce them, and shall indicate "Source: Mets Medicine" when authorizing reprints.
all reprinted articles on this website are for the purpose of transmitting more information and clearly indicate the source and author, and media or individuals who do not wish to be reproduced may contact us and we will delete them immediately.
at the same time reproduced content does not represent the position of this site.
leave a message here